Sionna Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Mike Cloonan
Chief executive officer
US$3.7m
Total compensation
| CEO salary percentage | 13.58% |
| CEO tenure | 4yrs |
| CEO ownership | 1.2% |
| Management average tenure | 3.7yrs |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$66m |
| Dec 31 2024 | US$4m | US$506k | -US$62m |
| Sep 30 2024 | n/a | n/a | -US$58m |
| Dec 31 2023 | US$754k | US$487k | -US$47m |
Compensation vs Market: Mike's total compensation ($USD3.73M) is about average for companies of similar size in the US market ($USD3.97M).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
CEO
Mike Cloonan (52 yo)
Mr. Michael Cloonan, M.B.A., also known as Mike, has been an Independent Director of bluebird bio, Inc. from June 20, 2024. He also serves as Advisor since February 2022 at RA Capital Management, L.P. He h...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4yrs | US$3.73m | 1.24% $ 7.7m | |
| CFO & Head of Corporate Development | 3.7yrs | US$1.30m | 0.28% $ 1.7m | |
| Chief Medical Officer | 3.9yrs | US$1.28m | 0.064% $ 400.9k | |
| Co-Founder & Senior VP of Discovery Research | 6.3yrs | no data | no data | |
| Co-founder & Senior VP of Medicinal Chemistry | 6.3yrs | no data | no data | |
| Vice President of Programs | no data | no data | no data | |
| Vice President of Information & Technology | 3.3yrs | no data | no data | |
| Chief Legal Officer | less than a year | no data | no data | |
| Chief People Officer | 2.5yrs | no data | no data | |
| Senior Vice President of Global Regulatory Affairs & Quality | 2.1yrs | no data | no data | |
| Senior Vice President of Chemistry | no data | no data | no data |
Experienced Management: SION's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4yrs | US$3.73m | 1.24% $ 7.7m | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Independent Director | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Independent Director | 4.9yrs | no data | no data | |
| Independent Director | 5.4yrs | no data | no data | |
| Independent Chairman | 2.9yrs | US$344.29k | 0% $ 0 | |
| Independent Director | 5.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Independent Director | less than a year | US$339.00k | no data | |
| Chair of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | no data | no data |
Experienced Board: SION's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/30 18:54 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sionna Therapeutics, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Salveen Richter | Goldman Sachs |
| Yatin Suneja | Guggenheim Securities, LLC |
| Paul Matteis | Stifel, Equities Research |